Literature DB >> 15712604

Immunity against the opportunistic fungal pathogen Pneumocystis.

Chad Steele1, Judd E Shellito, Jay K Kolls.   

Abstract

Species of the genus Pneumocystis exist as opportunistic fungal pathogens and are associated with severe pneumonia and pulmonary complications in immunocompromised individuals. Although prophylactic therapy for Pneumocystis has significantly decreased the overall incidence of infection, more than 80% of cases in current patient populations are considered breakthrough cases. In the HIV-infected population, in the years following the initiation of highly active antiretroviral therapy (HAART), significant reductions in the incidence of Pneumocystis infection were observed, although trends over the last several years suggest that the incidence of Pneumocystis has plateaued rather than decreased. Furthermore, with the more prominent usage of immunosuppressive therapies, the frequency of Pneumocystis infection in the HIV-negative population, such as those with hematologic malignancies and those who have undergone transplantation, has risen significantly. Investigating host defense mechanisms against P. carinii has historically been problematic due to the difficulty in achieving continuous in vitro propagation of proliferating Pneumocytis organisms. Nevertheless, clinical and experimental studies have documented that host defense against Pneumocystis involves a concerted effort between innate, cell-mediated (T lymphocyte) and humoral (B lymphocyte) responses. However, the pulmonary environment is a tissue site where heightened inflammatory responses can often lead to inflammation-mediated injury, thereby contributing to the pathogenesis of Pneumocystis infection. Accordingly, clearance of Pneumocystis from the pulmonary environment is dependent on a delicate equilibrium between the inflammatory response and immune-mediated clearance of the organism. Furthermore, innate and adaptive responses against Pneumocystis are strikingly similar to those against other medically-important fungi, thus providing additional evidence that Pneumocystis exists as a fungal organism.

Entities:  

Mesh:

Year:  2005        PMID: 15712604     DOI: 10.1080/13693780400015360

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

1.  Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection.

Authors:  Xiaowen L Rudner; Kyle I Happel; Erana A Young; Judd E Shellito
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

2.  HIV-1 Tat increases oxidant burden in the lungs of transgenic mice.

Authors:  Adela Cota-Gomez; Ariana C Flores; Xiao-Feng Ling; Marileila Varella-Garcia; Sonia C Flores
Journal:  Free Radic Biol Med       Date:  2011-08-05       Impact factor: 7.376

3.  Exogenous heat-killed Escherichia coli improves alveolar macrophage activity and reduces Pneumocystis carinii lung burden in infant mice.

Authors:  Kerry M Empey; Melissa Hollifield; Beth A Garvy
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

4.  Immune responses to Pneumocystis murina are robust in healthy mice but largely absent in CD40 ligand-deficient mice.

Authors:  Beatriz Hernandez-Novoa; Lisa Bishop; Carolea Logun; Peter J Munson; Eldad Elnekave; Zoila G Rangel; Jennifer Barb; Robert L Danner; Joseph A Kovacs
Journal:  J Leukoc Biol       Date:  2008-05-08       Impact factor: 4.962

5.  Pneumocystis jirovecii Rtt109, a novel drug target for Pneumocystis pneumonia in immunosuppressed humans.

Authors:  Jayme L Dahlin; Theodore Kottom; Junhong Han; Hui Zhou; Michael A Walters; Zhiguo Zhang; Andrew H Limper
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

6.  Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease.

Authors:  Alison Morris; Mahesh Netravali; Heather M Kling; Timothy Shipley; Ted Ross; Frank C Sciurba; Karen A Norris
Journal:  Clin Infect Dis       Date:  2008-10-01       Impact factor: 9.079

7.  Common variable immune deficiency in a Pomeranian with Pneumocystis carinii pneumonia.

Authors:  Hideyuki Kanemoto; Rei Morikawa; James Kenn Chambers; Koichi Kasahara; Yasuko Hanafusa; Kazuyuki Uchida; Koichi Ohno; Hiroyuki Nakayama
Journal:  J Vet Med Sci       Date:  2015-02-10       Impact factor: 1.267

Review 8.  Pattern recognition receptors in antifungal immunity.

Authors:  Anthony Plato; Sarah E Hardison; Gordon D Brown
Journal:  Semin Immunopathol       Date:  2014-11-25       Impact factor: 9.623

9.  Effects of clinical and environmental factors on bronchoalveolar antibody responses to Pneumocystis jirovecii: A prospective cohort study of HIV+ patients.

Authors:  Robert J Blount; Kieran R Daly; Serena Fong; Emily Chang; Katherine Grieco; Meredith Greene; Stephen Stone; John Balmes; Robert F Miller; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2017-07-10       Impact factor: 3.240

10.  IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients.

Authors:  Agnieszka Wójtowicz; Stéphanie Bibert; Patrick Taffé; Enos Bernasconi; Hansjakob Furrer; Huldrych F Günthard; Matthias Hoffmann; Michael Osthoff; Matthias Cavassini; Pierre-Yves Bochud
Journal:  AIDS       Date:  2019-09-01       Impact factor: 4.177

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.